But soon after, we realized we are making new ethical issues. What is needed before patients can receive stem cell treatments for the 10 or so diseases you identified?
We can make a human kidney or human pancreas in pigs if human i PS cells are injected into the embryo.
Well, we realized that it would take a great deal of time and would be unrealistically expensive to carry out the deep sequencing and animal studies for each patient’s cells. We can help just a small portion of patients by stem cell therapy. Parkinson’s disease is caused by failure of very specialized brain cells that produce dopamine.
How many compatible donor cell lines do you expect will be needed to cover the Japanese population? One particular line — just one — can work for 17 percent of the Japanese population. For example, target diseases for cell therapy are limited. Heart failure is caused by loss of function of cardiac heart cell. We can make that one type of cell from stem cells in a large amount, and by transplanting those cells, we should be able to rescue the patient.
I think it’s likely that clinical trials will be well underway for many of these diseases in the next decade.
Your discovery has not entirely replaced embryonic stem cells for potential treatments.In the meantime, to ensure continued support, we are displaying the site without styles and Java Script.Dieter Egli was just about to start graduate school in 1998 when researchers first worked out how to derive human embryonic stem cells.Still, many say that human embryonic stem cells are now more relevant than ever.“I am very excited about embryonic stem cells,” says Egli.In the two decades since, the prolific cells have been a fixture of his career.The biologist, now at Columbia University in New York City, has used them to explore how DNA from adult cells can be reprogrammed to an embryonic state, and to tackle questions about the development and treatment of diabetes.He has even helped to develop an entirely new form of human embryonic stem cell that could simplify studies on what different human genes do.His wide-ranging research established him as a leader in embryonic stem-cell biology, a field challenged by restricted funding and an enthusiasm for competing technologies that don’t carry the same ethical baggage. You are using a browser version with limited support for CSS.To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer).